Breaking News
‘Urgent medical attention’ advice for Mounjaro and Wegovy users - could be fatal
Key Points
‘Urgent medical attention’ advice for Mounjaro and Wegovy users - could be fatal Patients taking the popular weight-loss injections have been told what symptoms should never be ignored People using popular weight-loss injections have been reminded to act quickly if they develop a particular set of symptoms. The Medicines and Healthcare products Regulatory Agency (MHRA) issued an alert of a possible serious complication linked to these medicines, including rare reports of cases that have been...
‘Urgent medical attention’ advice for Mounjaro and Wegovy users - could be fatal
Patients taking the popular weight-loss injections have been told what symptoms should never be ignored
People using popular weight-loss injections have been reminded to act quickly if they develop a particular set of symptoms. The Medicines and Healthcare products Regulatory Agency (MHRA) issued an alert of a possible serious complication linked to these medicines, including rare reports of cases that have been fatal.
The warning, published on January 29, applies to glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP receptor agonists. This includes Wegovy, which contains semaglutide, and Mounjaro, which contains tirzepatide, as well as other medicines in the same groups.
People taking these could develop pancreatitis, which means inflammation of the pancreas, says the regulator. The MHRA says there have been rare reports of severe cases, including necrotising pancreatitis, where parts of the pancreas tissue die, and cases resulting in death.
Patients are advised to seek urgent medical attention if they experience severe and persistent abdominal pain. "Be alert to the risk of pancreatitis," reads a statement by the government agency.
"There have been rare reports of necrotising and fatal pancreatitis associated with GLP-1 and GLP-1/GIP receptor agonists. Advise patients to seek urgent medical attention if they develop severe and persistent abdominal pain that may radiate to the back and may be accompanied by nausea and vomiting."
The regulator warns that early symptoms can be difficult to distinguish from more common stomach-related side effects associated with these medicines. It says healthcare professionals should remain alert to the possibility of pancreatitis when assessing patients taking GLP-1 or GLP-1/GIP treatments.
There is also a reminder for people who obtain their injections privately, as these prescriptions may not appear on their usual medical records. The MHRA says clinicians should ask about use of these medicines if someone presents with symptoms that could indicate pancreatitis.
According to the regulator, treatment should be stopped immediately if pancreatitis is suspected. If the diagnosis is confirmed, patients should not restart the medicine, while those with a previous history of pancreatitis should use these treatments with caution.
Ensure our latest Health headlines always appear at the top of your Google Search by making us a Preferred Source. Click here to activate or add us as Preferred Source in your Google search settings
The MHRA also published figures showing it had received 1,296 Yellow Card reports of pancreatitis associated with GLP-1 and GLP-1/GIP medicines between 2007 and October 2025. Of those reports, 19 were recorded as fatal and 24 involved necrotising pancreatitis, although such reports do not in themselves prove that a medicine caused the condition.
Anyone who experiences the warning symptoms should seek "urgent medical attention" rather than waiting for them to pass. Suspected side effects can also be reported to the MHRA through its Yellow Card scheme.